CHF - Congestive Heart FailureADHERE-HFNCT07831538
Digital Outreach for Heart Failure Adherence
A study testing Digital Outreach in people with CHF - Congestive Heart Failure, run by Kaiser Permanente at 1 site in United States.
Trial summary
The goal of the ADHERE-HF study is to evaluate whether care-embedded, operationally delivered digital outreach improves medication refill, adherence, and clinical outcomes among adults with heart failure who are overdue for a refill of an eligible guideline-directed medical therapy (GDMT) medication. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- CHF - Congestive Heart Failure
- What is being tested?
- Digital Outreach
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13,714 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Sep 2026to Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Active KPNC membership
- Heart failure diagnosis documented at least 6 months before the index date, with a documented EF
- Prescribed at least one eligible GDMT medication for ≥6 months:
- HFpEF (EF≥50%): ARNI (sacubitril/valsartan); MRA; SGLT2i
- HFrEF or HFmrEF (EF <50%): ARNI (sacubitril/valsartan), ACEi, or ARB; Beta-blocker (bisoprolol, carvedilol, or sustained-release metoprolol succinate); MRA; SGLT2i
- At least one unfilled refill for an eligible GDMT medication that is 7-13 days overdue at index
Who cannot join
- Documented allergy or intolerance to all eligible GDMT medications for which the patient is overdue
- Receiving hospice or comfort-focused care
- Skilled nursing facility stay within prior 12 months
- No valid telephone number on file through which the patient could be reached by text message or automated telephone call
- Opted out of receiving pharmacy medication adherence outreach from Kaiser Permanente
- Other conditions that prevent outreach
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Kaiser Permanente Division of Research
Pleasanton, California, 94588
About this study
Official title: Adherence Through Digital Health: Evaluating Randomized Engagement in Heart Failure
The goal of the ADHERE-HF study is to evaluate whether care-embedded, operationally delivered digital outreach improves medication refill, adherence, and clinical outcomes among adults with heart failure who are overdue for a refill of an eligible guideline-directed medical therapy (GDMT) medication.
The main question it aims to answer is: Does digital outreach using interactive text messages or automated telephone calls increase short-term refill of overdue heart failure medications compared with usual care?
The study will evaluate the effectiveness of a digital outreach strategy delivered through existing health system communication channels. Members who have opted in to pharmacy text messaging will receive interactive text messages, while those who have not opted in will receive an interactive automated telephone call. The comparison group will receive usual care with no additional outreach.
Read the detailed description
Heart failure is a common chronic condition associated with hospitalization, impaired quality of life, and premature death. Guideline-directed medical therapy (GDMT) can reduce the risk of cardiovascular death and worsening heart failure, but patients must continue to refill and take these medications to receive their full benefit. Medication nonadherence remains common and contributes to a gap between the benefits observed in clinical trials and those achieved in routine care. The ADHERE-HF study is a pragmatic, prospective, open-label, individual-level randomized clinical trial designed to evaluate whether digital outreach improves refill of overdue GDMT medications among adults with heart failure. The study will compare a text-first digital outreach strategy with usual care and will be conducted through existing health system pharmacy operations.
Eligible members will be randomized in a 1:1 ratio to operationally conducted digital outreach or usual care. Randomization will be stratified by ejection fraction category and by whether the member has opted in to pharmacy text outreach at the time of randomization. Members assigned to digital outreach who have opted in to pharmacy text messaging will receive interactive two-way text messages. These messages notify members that they may be due for a medication refill and provide options to request mail-order delivery or pharmacy pickup. Responses indicating medication, cost, dosing, or other concerns may be referred to pharmacy staff for follow-up. Members assigned to digital outreach who have not opted in to pharmacy text messaging will receive an interactive automated telephone call. The call allows members to select among refill options using the telephone keypad. Members may request refill at their usual pharmacy, use or establish mail-order delivery, or transfer to a pharmacy representative for assistance. Members assigned to usual care will receive no additional outreach. All members will continue to receive routine pharmacy refill communications and other standard health system services. Members will remain assigned to their randomized strategy for 12 months. If any eligible GDMT medication becomes overdue during follow-up, members in the digital outreach group may receive additional outreach. Outreach modality will be based on each member's pharmacy text opt-in status at the time of each contact.
The primary outcome is refill, within 14 days of the outreach date, of at least one GDMT medication that was overdue at randomization. Secondary outcomes include refill within 28 days, the proportion of overdue medications refilled, time to first refill, mail-order fulfillment, medication adherence and persistence at 6 and 12 months, heart failure hospitalization, and all-cause mortality. All outcomes will be obtained from routinely collected, operationally available pharmacy dispensing, electronic health record, administrative, and digital communication data.
The study has no study-specific visits or any direct contact by the study team. This study is designed to generate care-embedded, actionable evidence within a learning health system by determining whether scalable digital outreach improves refill and adherence to guideline-directed heart failure medications and whether the strategy should be implemented more broadly.
- Conditions
- CHF - Congestive Heart Failure
- Being tested
- Digital Outreach
- Keywords
- Heart failure, Heart failure management, Guideline-directed medical therapy, GDMT, Medication adherence, Medication nonadherence, Medication refill, Digital outreach, Patient outreach, Text messaging, SMS, Automated telephone calls, Interactive voice response, Pharmacy outreach, Pragmatic randomized trial, Learning health system
- Medical subject headings
- Heart Failure, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital OutreachBehavioural
Participants assigned to this arm will receive digital outreach encouraging refill of overdue guideline-directed medical therapy (GDMT) medications for heart failure. Participants who have opted in to pharmacy text messaging at the time of outreach will receive interactive text messages. Participants who have not opted in to pharmacy text messaging will receive an interactive automated telephone call. Participants may receive additional outreach during the 12-month intervention period if another eligible GDMT medication becomes overdue.
| Study group | Role | What they receive |
|---|---|---|
| Digital Outreach | Experimental | Participants will receive interactive text messages or automated phone calls encouraging refill of overdue heart failure medications. Receives: Behavioral: Digital Outreach |
| Usual Care | No intervention | Participants in this arm will receive usual care with no proactive outreach during the study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Refill of at least one overdue GDMT medication (within 14 days)
Proportion of participants who refill at least one guideline-directed medical therapy (GDMT) medication for which they were overdue at randomization (index) based on pharmacy dispensing records.
Measured: Within 14 days after outreach
Secondary outcomes (11)
Composite of heart failure hospitalization or all-cause death
Time to first occurrence of heart failure hospitalization or death from any cause.
Measured: Up to 12 months after randomization
Time to first refill of an overdue GDMT medication
Time from outreach to refill of any GDMT medication for which the participant was overdue at randomization, measured using pharmacy dispensing records. Participants who do not refill will be censored at disenrollment, death, or 28 days after outreach.
Measured: Up to 28 days after outreach
Refill of at least one overdue GDMT medication (within 28 days)
Proportion of participants who refill at least one GDMT medication for which they were overdue at randomization, based on pharmacy dispensing records.
Measured: Within 28 days after outreach
Proportion of overdue GDMT medications refilled (within 14 days)
For each participant, the proportion of GDMT medications overdue at randomization that are refilled, determined from pharmacy dispensing records.
Measured: Within 14 days after outreach
Proportion of overdue GDMT medications refilled (within 28 days)
For each participant, the proportion of GDMT medications overdue at randomization that are refilled, determined from pharmacy dispensing records.
Measured: Within 28 days after outreach
Heart failure hospitalization
Time to first heart failure hospitalization.
Measured: Up to 12 months after randomization
All-cause death
Time to death from any cause
Measured: Up to 12 months after randomization
Recurrent heart failure hospitalizations
Total number of heart failure hospitalizations occurring during follow-up.
Measured: Up to 12 months after randomization
Mail-order fulfillment
Proportion of participants who receive a mail-order dispense for at least one GDMT medication that was overdue at randomization.
Measured: Within 14 days after outreach
GDMT adherence (proportion of days covered)
Adherence to GDMT measured as proportion of days covered (PDC). PDC will be calculated separately by GDMT class and overall across prescribed classes.
Measured: At 6 months and 12 months after randomization
GDMT persistence
Persistence with GDMT therapy, defined as time to the first gap in medication supply exceeding 60 days. Persistence will be evaluated separately by GDMT class prescribed.
Measured: At 6 months and 12 months after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2026
- Study start21 Sep 2026 (estimated)
- Primary completionMar 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CHF - Congestive Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 13,714 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kaiser Permanente
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07831538
- Sponsor's protocol ID
- ADHERE-HF
- Acronym
- ADHERE-HF
- Status last verified
- Aug 2026
- First submitted
- 13 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adherence Through Digital Health: Evaluating Randomized Engagement in Heart Failure
- ClinicalTrials.gov ID
- NCT07831538
- Acronym / sponsor ID
- ADHERE-HF / ADHERE-HF
- Conditions
- CHF - Congestive Heart Failure
- Keywords
- Heart failure, Heart failure management, Guideline-directed medical therapy, GDMT, Medication adherence, Medication nonadherence, Medication refill, Digital outreach
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 13,714 participants (estimated)
- Lead sponsor
- Kaiser PermanenteUniversity, hospital or other
- Study start
- 21 Sep 2026 (estimated)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 21 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of the ADHERE-HF study is to evaluate whether care-embedded, operationally delivered digital outreach improves medication refill, adherence, and clinical outcomes among adults with heart failure who are overdue for a refill of an eligible guideline-directed medical therapy (GDMT) medication.
The main question it aims to answer is: Does digital outreach using interactive text messages or automated telephone calls increase short-term refill of overdue heart failure medications compared with usual care?
The study will evaluate the effectiveness of a digital outreach strategy delivered through existing health system communication channels. Members who have opted in to pharmacy text messaging will receive interactive text messages, while those who have not opted in will receive an interactive automated telephone call. The comparison group will receive usual care with no additional outreach.
Detailed description
Heart failure is a common chronic condition associated with hospitalization, impaired quality of life, and premature death. Guideline-directed medical therapy (GDMT) can reduce the risk of cardiovascular death and worsening heart failure, but patients must continue to refill and take these medications to receive their full benefit. Medication nonadherence remains common and contributes to a gap between the benefits observed in clinical trials and those achieved in routine care. The ADHERE-HF study is a pragmatic, prospective, open-label, individual-level randomized clinical trial designed to evaluate whether digital outreach improves refill of overdue GDMT medications among adults with heart failure. The study will compare a text-first digital outreach strategy with usual care and will be conducted through existing health system pharmacy operations.
Eligible members will be randomized in a 1:1 ratio to operationally conducted digital outreach or usual care. Randomization will be stratified by ejection fraction category and by whether the member has opted in to pharmacy text outreach at the time of randomization. Members assigned to digital outreach who have opted in to pharmacy text messaging will receive interactive two-way text messages. These messages notify members that they may be due for a medication refill and provide options to request mail-order delivery or pharmacy pickup. Responses indicating medication, cost, dosing, or other concerns may be referred to pharmacy staff for follow-up. Members assigned to digital outreach who have not opted in to pharmacy text messaging will receive an interactive automated telephone call. The call allows members to select among refill options using the telephone keypad. Members may request refill at their usual pharmacy, use or establish mail-order delivery, or transfer to a pharmacy representative for assistance. Members assigned to usual care will receive no additional outreach. All members will continue to receive routine pharmacy refill communications and other standard health system services. Members will remain assigned to their randomized strategy for 12 months. If any eligible GDMT medication becomes overdue during follow-up, members in the digital outreach group may receive additional outreach. Outreach modality will be based on each member's pharmacy text opt-in status at the time of each contact.
The primary outcome is refill, within 14 days of the outreach date, of at least one GDMT medication that was overdue at randomization. Secondary outcomes include refill within 28 days, the proportion of overdue medications refilled, time to first refill, mail-order fulfillment, medication adherence and persistence at 6 and 12 months, heart failure hospitalization, and all-cause mortality. All outcomes will be obtained from routinely collected, operationally available pharmacy dispensing, electronic health record, administrative, and digital communication data.
The study has no study-specific visits or any direct contact by the study team. This study is designed to generate care-embedded, actionable evidence within a learning health system by determining whether scalable digital outreach improves refill and adherence to guideline-directed heart failure medications and whether the strategy should be implemented more broadly.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Digital Outreach | Experimental | Behavioral: Digital OutreachParticipants will receive interactive text messages or automated phone calls encouraging refill of overdue heart failure medications. |
| Usual Care | No intervention | –Participants in this arm will receive usual care with no proactive outreach during the study period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥18 years
- Active KPNC membership
- Heart failure diagnosis documented at least 6 months before the index date, with a documented EF
- Prescribed at least one eligible GDMT medication for ≥6 months:
- At least one unfilled refill for an eligible GDMT medication that is 7-13 days overdue at index
Key exclusion criteria (6 listed)
- Documented allergy or intolerance to all eligible GDMT medications for which the patient is overdue
- Receiving hospice or comfort-focused care
- Skilled nursing facility stay within prior 12 months
- No valid telephone number on file through which the patient could be reached by text message or automated telephone call
- Opted out of receiving pharmacy medication adherence outreach from Kaiser Permanente
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital OutreachParticipants assigned to this arm will receive digital outreach encouraging refill of overdue guideline-directed medical therapy (GDMT) medications for heart failure. Participants who have opted in to pharmacy text messaging at the time of outreach will receive interactive text messages. Participants who have not opted in to pharmacy text messaging will receive an interactive automated telephone call. Participants may receive additional outreach during the 12-month intervention period if another eligible GDMT medication becomes overdue. | Behavioural | Digital Outreach |
Primary outcome
Refill of at least one overdue GDMT medication (within 14 days)
Time frame: Within 14 days after outreach
Proportion of participants who refill at least one guideline-directed medical therapy (GDMT) medication for which they were overdue at randomization (index) based on pharmacy dispensing records.
11 secondary outcomes
Composite of heart failure hospitalization or all-cause death
Time frame: Up to 12 months after randomization
Time to first refill of an overdue GDMT medication
Time frame: Up to 28 days after outreach
Refill of at least one overdue GDMT medication (within 28 days)
Time frame: Within 28 days after outreach
Proportion of overdue GDMT medications refilled (within 14 days)
Time frame: Within 14 days after outreach
Proportion of overdue GDMT medications refilled (within 28 days)
Time frame: Within 28 days after outreach
Heart failure hospitalization
Time frame: Up to 12 months after randomization
All-cause death
Time frame: Up to 12 months after randomization
Recurrent heart failure hospitalizations
Time frame: Up to 12 months after randomization
Mail-order fulfillment
Time frame: Within 14 days after outreach
GDMT adherence (proportion of days covered)
Time frame: At 6 months and 12 months after randomization
GDMT persistence
Time frame: At 6 months and 12 months after randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for CHF - Congestive Heart Failure
Recruiting
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
Cardiogenic Shock, Acute Myocardial Infarction of Inferior Wall
RecruitingPhase 4
DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
Pulmonary Edema, Congestive Heart Failure
Recruiting
Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
Acute Coronary Syndrome, Heart Failure
Recruiting
Peripheral Venous Pressure (PVP) Trial
Congestive Heart Failure
Active, not recruitingPhase 4
PVP-Guided Decongestive Therapy in HF 2
Heart Failure, Congestion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital Outreach in people with CHF - Congestive Heart Failure, run by Kaiser Permanente at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Refill of at least one overdue GDMT medication (within 14 days) (time frame: Within 14 days after outreach). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.